4D Molecular Therapeutics (FDMT) – Research Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of 4D Molecular Therapeutics (NASDAQ: FDMT) in the last few weeks:

• 7/31/2026 – 4D Molecular Therapeutics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $37.00 price target on the stock.
• 7/28/2026 – 4D Molecular Therapeutics was upgraded by Chardan Capital to “strong-buy”.
• 7/20/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
• 7/17/2026 – 4D Molecular Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 197,226 shares of company stock valued at $2,200,677 over the last three months. 7.90% of the stock is currently owned by insiders.

Get 4D Molecular Therapeutics Inc alerts:

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Featured Stories

• Five stocks we like better than 4D Molecular Therapeutics
• What Tesla Stands to Lose If It Walks Away From China
• Disney Sets Up for a Magical Year in 2027
• Astera Labs’ Post-Earnings Pullback May Be Last Chance to Buy Below $360
• McDonald’s Stock Sell-Off: Justified Warning or Buying Opportunity?

Receive News & Ratings for 4D Molecular Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.